Rituximab biosimilar and reference rituximab in patients with previously untreated advanced follicular lymphoma (ASSIST-FL): primary results from a confirmatory phase 3, double-blind, randomised, controlled study-Reference-Cited by-同舟云学术

Rituximab biosimilar and reference rituximab in patients with previously untreated advanced follicular lymphoma (ASSIST-FL): primary results from a confirmatory phase 3, double-blind, randomised, controlled study

Published:2017-08 Issue:8 Volume:4 Page:e350-e361
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Jurczak Wojciech,Moreira Ilídia,Kanakasetty Govind Babu,Munhoz Eduardo,Echeveste Maria Asunción,Giri Pratyush,Castro Nelson,Pereira Juliana,Akria Luiza,Alexeev Sergey,Osmanov Eugeniy,Zhu Peijuan,Alexandrova Siyka,Zubel Angela,Harlin Olof,Amersdorffer Jutta

Publisher

Elsevier BV

Subject

Hematology

Reference25 articles.

1. Mechanism of action of CD20 antibodies;Boross;Am J Cancer Res,2012

2. Rituximab in the treatment of non-Hodgkin's lymphoma;Hauptrock;Biologics,2008

3. Rituximab maintenance improves overall survival of patients with follicular lymphoma—individual patient data meta-analysis;Vidal;Eur J Cancer,2017

4. Rituximab: the first monoclonal antibody approved for the treatment of lymphoma;Grillo-López;Curr Pharm Biotechnol,2000

5. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow up;Dreyling;Ann Oncol,2016

Cited by 69 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Revisions to the requirement of the Japanese clinical study data for biosimilar developments in Japan;Expert Opinion on Biological Therapy;2024-07-02

2. Survey of Data Package and Sample Size of Comparative Clinical Studies for Biosimilar Developments from PMDA Assessments;Pharmaceutical Medicine;2024-04-29

3. Biosimilar in Cervical Cancer;Biosimilars for Cancer Treatment;2024

4. The comparison of safety and cost between reference drug of rituximab and its biosimilar Riximyo in lymphoproliferative disorders and other hematological diseases. Single center experience;Leukemia & Lymphoma;2023-10-27

5. Clinical Benefit, Price, and Uptake for Cancer Biosimilars vs Reference Drugs in China;JAMA Network Open;2023-10-12